Verisim Life, Inc.
VeriSIM Life is dedicated to transforming drug discovery and development through innovative AI-driven science. Founded in 2017 by Dr. Jo Varshney, the company aims to eliminate inaccuracy and waste in translating drug candidates to clinical trials by leveraging AI and multidisciplinary methods to predict patient outcomes, thereby accelerating the development of groundbreaking therapies and improving success rates.
Industries
Nr. of Employees
small (1-50)
Verisim Life, Inc.
San Francisco, California, United States, North America
Products
Translational decision-support platform
A platform that integrates mechanistic simulations with machine learning to predict patient-level drug behavior and produce a quantitative translational score to inform discovery and development decisions.
Collaborative AI-assisted molecule design environment
An interactive design environment combining generative algorithms with human-in-the-loop inputs to produce diverse, high-potential candidate structures in real time.
Translational decision-support platform
A platform that integrates mechanistic simulations with machine learning to predict patient-level drug behavior and produce a quantitative translational score to inform discovery and development decisions.
Collaborative AI-assisted molecule design environment
An interactive design environment combining generative algorithms with human-in-the-loop inputs to produce diverse, high-potential candidate structures in real time.
Services
AI-driven translational modeling services
Collaborative engagements that apply integrated mechanistic and machine-learning models to de-risk discovery and accelerate translational decisions across preclinical and clinical stages.
Virtual patient generation and trial augmentation
Generation and use of synthetic patient cohorts and imputation methods to enrich datasets, support stratification, and evaluate trial outcomes in silico.
Regulatory and MIDD advisory services
Support for preparing computational evidence and aligning model outputs with regulatory guidance for inclusion in submissions and regulatory interactions.
AI-driven translational modeling services
Collaborative engagements that apply integrated mechanistic and machine-learning models to de-risk discovery and accelerate translational decisions across preclinical and clinical stages.
Virtual patient generation and trial augmentation
Generation and use of synthetic patient cohorts and imputation methods to enrich datasets, support stratification, and evaluate trial outcomes in silico.
Regulatory and MIDD advisory services
Support for preparing computational evidence and aligning model outputs with regulatory guidance for inclusion in submissions and regulatory interactions.
Expertise Areas
- AI-enabled preclinical development
- Model-informed drug development (MIDD)
- Mechanistic PK/PD modeling (PBPK, QSP)
- Virtual clinical trial simulation and design
Key Technologies
- Hybrid AI (knowledge-enhanced AI)
- Deep learning / machine learning
- Mechanistic biosimulation (PBPK, QSP)
- Virtual patient simulation